5 january 2023 |
|
09:00 |
Acasti Pharma Inc. ("Acasti" or the "Company") , a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced that it will host a conference call on Tuesday, January 10,... |
07:50 |
Curative Biotechnology Inc. ("Curative Biotech" or the "Company"), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today that it has successfully completed its Investigational New Drug... |
4 january 2023 |
|
14:00 |
Two women scientists were announced King Faisal Prize for Medicine and Science laureates for 2023: a Covid-19 vaccine developer and a nanotechnology scientist. Six others were announced King Faisal Prize laureates for having enriched humanity with... |
3 january 2023 |
|
07:30 |
Evaxion Biotech A/S ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that the U.S. Food and Drug Administration ("FDA") determined that the Company may... |
29 december 2022 |
|
01:35 |
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announces the online... |
28 december 2022 |
|
08:00 |
Acasti Pharma Inc. ("Acasti" or the "Company") , a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announces that the preliminary topline results of the pharmacokinetic (PK)... |
22 december 2022 |
|
14:05 |
Revive Therapeutics Ltd. ("Revive" or the "Company") , a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced that it has submitted the Type C meeting request... |
09:00 |
Ceapro Inc. ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced... |
07:50 |
Small Pharma Inc. (the "Company" or "Small Pharma"), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that the last patient has completed its... |
21 december 2022 |
|
14:00 |
First in human clinical study provides proof-of-concept for mitochondrial augmentation therapy platform, which enables use of healthy mitochondria to improve mitochondrial function and mitigate effects of large-scale mitochondrial DNA (mtDNA)... |
19 december 2022 |
|
07:00 |
XORTX Therapeutics Inc. ("XORTX" or the "Company") , a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the completion of dosing in the XRX-OXY-101... |
15 december 2022 |
|
07:50 |
Small Pharma Inc. (the "Company" or "Small Pharma"), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today confirms that the first patient has been dosed in the Company's Phase Ib drug... |
14 december 2022 |
|
07:35 |
Avicanna Inc. ("Avicanna" or the "Company") , a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it will be initiating an... |
12 december 2022 |
|
08:30 |
ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today findings from a safety and efficacy retrospective analysis comparing outcomes of patients treated with ECT-001 (UM171-expanded) Cell Therapy... |
11 december 2022 |
|
09:00 |
Company Provides Comprehensive Clinical Update from Phase 1/2 TrialTuspetinib Continues to Deliver Single Agent Responses in r/r AML PatientsTuspetinib Safety and Efficacy Profile may Position Drug to Become the Preferred Kinase Inhibitor for Triplet... |
9 december 2022 |
|
07:30 |
Biogen Inc. ? announced that the U.S. Food and Drug Administration (FDA) has accepted for review the abbreviated Biologics License Application (aBLA) for BIIB800, a biosimilar candidate referencing ACTEMRA®1 (tocilizumab), an anti-interleukin-6... |
8 december 2022 |
|
09:00 |
Sirona Biochem Corp. ("Sirona") is pleased to announce that the clinical trial, for novel anti-aging compound TFC-1326, started on December 5th, 2022. The trial, which will take place in Paris, is designed to assess the compound's efficacy in... |
6 december 2022 |
|
07:05 |
Lucira COVID-19 & Flu Test is the first and only combination over-the-counter self-test with fast, molecular lab-quality results enabling mass testing of symptomatic residents, staff and visitors amid the aggressive COVID-19 and flu season in... |
1 december 2022 |
|
18:35 |
Theratechnologies Inc. ("Theratechnologies" or the "Company") , a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its... |
28 november 2022 |
|
08:00 |
Providence Therapeutics Holdings Inc. ("Providence") today announced that Aleksandra Pastrak, M.D., Ph.D., chief medical officer of Providence Therapeutics, will deliver a... |
06:35 |
AXS-05 statistically significantly delayed time to relapse of Alzheimer's disease agitation versus placebo (p=0.014, primary endpoint) AXS-05 statistically significantly prevented relapse of Alzheimer's disease agitation versus placebo (p=0.018,... |
17 november 2022 |
|
07:00 |
Evaxion Biotech A/S ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced promising clinical data from the Phase 1/2a first-in-human study of its DNA-based... |
16 november 2022 |
|
09:00 |
Sirona Biochem Corp. ("Sirona") is pleased to announce positive results of the clinical safety study for their novel anti-aging compound TFC-1326 1% in formulation, now proven to be a non-irritant and non-sensitizer. TFC-1326, Sirona's lead... |
08:00 |
Sunshine Biopharma Inc. , a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals today announced that it has entered into a collaboration agreement with one of... |
07:00 |
InMed Pharmaceuticals Inc. ("InMed" or the "Company") , a leader in the pharmaceutical research, development and manufacturing of rare... |
07:00 |
Algernon Pharmaceuticals Inc. (the "Company" or "Algernon") , a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has commenced screening subjects for its Phase 1 clinical study of an intravenous formulation... |
15 november 2022 |
|
08:10 |
Organovo Holdings, Inc. , a three-dimensional biology (3D biology) company focused on delivering scientific and medical breakthroughs using novel technologies including 3D bioprinting, today announced that it has successfully advanced the use of its... |
08:05 |
Dr. Pierre Debs, Ph.D. announced today the launch of Chain Pharmaceuticals GmbH, a phytocannabinoid drug discovery company leveraging machine learning and real world medical data in the development of clinically proven plant-based medicines for... |
14 november 2022 |
|
07:30 |
Aptose Biosciences Inc. ("Aptose") , a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced dosing of the first patient to receive a continuous dosing regimen of the G3... |
10 november 2022 |
|
09:05 |
Medicenna Therapeutics Corp. ("Medicenna" or "the Company") , a clinical stage immunotherapy company, today... |
04:10 |
Evaxion Biotech A/S ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that it intends to further increase its focus on its lead oncology assets EVX-01... |
1 november 2022 |
|
16:05 |
HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after discontinuing AB-729 and NA therapy Preclinical data suggest that AB-101, an oral PD-L1 inhibitor, in combination with an RNAi, may provide enhanced HBV... |
31 october 2022 |
|
07:50 |
Small Pharma Inc. (the "Company" or "Small Pharma"), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that it has received... |
25 october 2022 |
|
13:45 |
Covis Pharma Group ("Covis"), a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses, today announced positive topline results from the AVANT phase 3 clinical... |
20 october 2022 |
|
07:00 |
Bright Peak Therapeutics, a privately held biotechnology company developing... |
14 october 2022 |
|
13:35 |
Revive Therapeutics Ltd. ("Revive" or the "Company") , a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has finalized an amended protocol to the... |
13 october 2022 |
|
09:25 |
IntelGenx Corp. (the "Company" or "IntelGenx") today provided an update on its collaboration with its strategic partner, atai Life Sciences ("atai"), for the development of novel formulations of pharmaceutical-grade psychedelics based on... |
08:35 |
Findings from this collaborative project with the University of Alberta using a unique surgical methodology illustrate how PGX-processed carriers can successfully be uniformly loaded with a fat-soluble active ingredient to generate superior bioactive... |
12 october 2022 |
|
08:40 |
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. ("Coherus") today announced the publication of toripalimab plus chemotherapy for patients with treatment-naïve advanced non-small cell... |
11 october 2022 |
|
08:40 |
ChristianaCare, a leading non-profit health system in the mid-Atlantic region, today announced it has spun out its first commercial biotechnology private start-up company, named CorriXR Therapeutics. CorriXR Therapeutics (pronounced Cor-ix-er; from... |
5 october 2022 |
|
07:00 |
Mindset Pharma Inc. ("Mindset" or the "Company"), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs,... |
4 october 2022 |
|
09:25 |
Spectral Medical Inc. ("Spectral" or the "Company") , a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market... |
08:00 |
Kane Biotech Inc. (the "Company" or "Kane Biotech") today announces that it has received an additional $425,000 USD of funding for its DispersinB Hydrogel® related to its Medical Technology Enterprise Consortium Research Project Award which was... |
3 october 2022 |
|
06:30 |
Axsome Therapeutics,... |
28 september 2022 |
|
07:15 |
Resverlogix Corp. ("Resverlogix" or the "Company") today announced that apabetalone's future clinical development related to COVID-19 will focus on the prevention and treatment of Post COVID-19 Conditions (PCC), colloquially known as long-COVID, as... |
26 september 2022 |
|
08:05 |
Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel immunotherapy platform designed to restore innate immune function, is pleased to announce it has received Health Canada clearance... |
21 september 2022 |
|
17:20 |
Biogen Inc. today announced that The... |
19 september 2022 |
|
07:30 |
Small Pharma Inc. (the "Company" or "Small Pharma"), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that it has completed enrollment in the Phase IIa clinical trial of... |
07:00 |
Psyence Group Inc. ("Psyence" or the "Company"), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is delighted to announce that it has received approval for its Phase IIa clinical trial... |
16 september 2022 |
|
07:00 |
Ketamine was safe, well-tolerated with 100% of patients treated with ketamine demonstrating reduction in dyskinesias as measured by the Unified Dyskinesia Rating Scale (UDysRS) UDysRS showed a 51% reduction from baseline during Infusion 2 (p=0.003),... |